Rule 17 Disclosure | 03-Aug-2023 | 12:38 | RNS |
Return of rights to Sulforadex from Juvenescence | 02-Aug-2023 | 07:00 | RNS |
Result of AGM | 21-Jul-2023 | 12:02 | RNS |
Notice of AGM & Posting of Annual Report | 20-Jun-2023 | 13:59 | RNS |
Grant Success for Glioblastoma studies | 19-Jun-2023 | 07:00 | RNS |
Final Results | 07-Jun-2023 | 07:00 | RNS |
Notice of Results | 26-May-2023 | 11:00 | RNS |
Preliminary results from Phase 1b study | 22-Mar-2023 | 07:00 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 14:00 | RNS |
Second Price Monitoring Extn | 16-Mar-2023 | 11:05 | RNS |
Price Monitoring Extension | 16-Mar-2023 | 11:00 | RNS |
No exposure to Silicon Valley Bank | 13-Mar-2023 | 07:00 | RNS |
Clinical trial update | 25-Jan-2023 | 07:00 | RNS |
Grant of Options - Director/PDMR Shareholding | 14-Dec-2022 | 17:08 | RNS |
Half-year Report | 08-Dec-2022 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 0.78p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 4.05 |
52 Week Low | 0.75 |
Volume | 745,046 |
Shares Issued | 427.35m |
Market Cap | £3.31m |
RiskGrade | 304 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
14:22 | 300,000 @ 0.78p |
13:45 | 250,000 @ 0.78p |
10:19 | 128,258 @ 0.78p |
10:17 | 59,096 @ 0.78p |
09:26 | 7,692 @ 0.75p |
You are here: research